CD33 and acute myeloid leukemia: Although expression intensity can be higher in AML bulk cells and/or LSCs, target-antigen candidates such as CD33 and CD123 are frequently found on hematopoietic stem cells (HSCs), resulting in the risk of long-lasting or even permanent myelosuppression [10].